Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
NCT ID: NCT01426230
Last Updated: 2013-03-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
201 participants
OBSERVATIONAL
2011-09-30
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)
NCT01623271
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
NCT00636636
Study of Gralise to Treat Fibromyalgia Patients
NCT02052414
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
NCT00335933
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
NCT00617461
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label
Cohort by age-
\- Patients \>70 Yrs old
No interventions assigned to this group
Open label
Cohort by age-
\- Patients \< 70 Yrs old
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient has hypersensitivity to gabapentin
* Patient has an estimated creatinine clearance of \<30 mL/min or is in hemodialysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Depomed
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rekha Sathyanarayana
Role: STUDY_DIRECTOR
Depomed Clinical Operations
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile, Alabama, United States
Tuscaloosa, Alabama, United States
Phoenix, Arizona, United States
Sun City, Arizona, United States
Tucson, Arizona, United States
Fresno, California, United States
San Francisco, California, United States
Fairfield, Connecticut, United States
Lauderdale Lakes, Florida, United States
Naples, Florida, United States
North Palm Beach, Florida, United States
Ormond Beach, Florida, United States
Palm Beach, Florida, United States
Sunrise, Florida, United States
Marietta, Georgia, United States
Bolingbrook, Illinois, United States
Evansville, Indiana, United States
Lexington, Kentucky, United States
Brighton, Massachusetts, United States
Worcestor, Massachusetts, United States
Jefferson City, Missouri, United States
St Louis, Missouri, United States
Tom River, New Jersey, United States
Hickory, North Carolina, United States
Raleigh, North Carolina, United States
Allentown, Pennsylvania, United States
Altoona, Pennsylvania, United States
Wyomissing, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Cordova, Tennessee, United States
Austin, Texas, United States
Bedford, Texas, United States
Corpus Christi, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Orem, Utah, United States
Edmonds, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mehta N, Bucior I, Bujanover S, Shah R, Gulati A. Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin. Health Qual Life Outcomes. 2016 Apr 1;14:54. doi: 10.1186/s12955-016-0456-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
81-0067
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.